Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
120
-
Total 13F shares, excl. options
-
67.8M
-
Shares change
-
+8.39M
-
Total reported value, excl. options
-
$129M
-
Value change
-
+$16.4M
-
Put/Call ratio
-
4.06
-
Number of buys
-
66
-
Number of sells
-
-33
-
Price
-
$1.90
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q4 2024
142 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q4 2024.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 120 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 67.8M shares
of 236M outstanding shares and own 28.72% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (15.1M shares), VANGUARD GROUP INC (10.9M shares), STATE STREET CORP (6.3M shares), Alerce Investment Management, L.P. (5.75M shares), GEODE CAPITAL MANAGEMENT, LLC (4.8M shares), RENAISSANCE TECHNOLOGIES LLC (3.82M shares), MORGAN STANLEY (1.79M shares), NORTHERN TRUST CORP (1.69M shares), CITADEL ADVISORS LLC (1.38M shares), and JACOBS LEVY EQUITY MANAGEMENT, INC (1.23M shares).
This table shows the top 120 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.